MannKind Corporation (MNKD) Latest News: $40M Financing for Afrezza, Rating Reiterated by Zacks, Price Target & More

MannKind's positive take on interim Phase III data for its inhaled insulin Afrezza has a big sweetener tied to it.

Keep Reading →